Strickler, J., Nakamura, Y., Shitara, K., Catenacci, D., Janjigian, Y., Barzi, A., … Marshall, J. (2021). P-174 MOUNTAINEER-02: Phase 2/3 study of tucatinib, trastuzumab, ramucirumab, and paclitaxel in previously treated HER2+ gastric or gastroesophageal junction adenocarcinoma: Trial in progress. In Annals of Oncology (Vol. 32, pp. S159–S159). Elsevier BV. https://doi.org/10.1016/j.annonc.2021.05.229

Strickler, J., Y. Nakamura, K. Shitara, D. Catenacci, Y. Janjigian, A. Barzi, T. Bekaii-Saab, et al. “P-174 MOUNTAINEER-02: Phase 2/3 study of tucatinib, trastuzumab, ramucirumab, and paclitaxel in previously treated HER2+ gastric or gastroesophageal junction adenocarcinoma: Trial in progress.” In Annals of Oncology, 32:S159–S159. Elsevier BV, 2021. https://doi.org/10.1016/j.annonc.2021.05.229.

Strickler J, Nakamura Y, Shitara K, Catenacci D, Janjigian Y, Barzi A, et al. P-174 MOUNTAINEER-02: Phase 2/3 study of tucatinib, trastuzumab, ramucirumab, and paclitaxel in previously treated HER2+ gastric or gastroesophageal junction adenocarcinoma: Trial in progress. In: Annals of Oncology. Elsevier BV; 2021. p. S159–S159.

Strickler, J., et al. “P-174 MOUNTAINEER-02: Phase 2/3 study of tucatinib, trastuzumab, ramucirumab, and paclitaxel in previously treated HER2+ gastric or gastroesophageal junction adenocarcinoma: Trial in progress.” Annals of Oncology, vol. 32, Elsevier BV, 2021, pp. S159–S159. Crossref, doi:10.1016/j.annonc.2021.05.229.

Strickler J, Nakamura Y, Shitara K, Catenacci D, Janjigian Y, Barzi A, Bekaii-Saab T, Lenz H, Lee J, Van Cutsem E, Chung H, Tabernero J, Yoshino T, Siena S, Garrido-Mayor J, Palanca-Wessels M, Xie D, Marshall J. P-174 MOUNTAINEER-02: Phase 2/3 study of tucatinib, trastuzumab, ramucirumab, and paclitaxel in previously treated HER2+ gastric or gastroesophageal junction adenocarcinoma: Trial in progress. Annals of Oncology. Elsevier BV; 2021. p. S159–S159.